Primary Sarcomatoid Malignant Mesothelioma of the Pancreas

Zhao, Yajie; Li, Zhuo; Wang, Chengfeng

doi:10.1007/s11605-018-3994-4

Cited by 1 publication

(1 citation statement)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Primary small intestinal tumours are relatively rare gastrointestinal neoplasms, accounting for less than 5% of all gastrointestinal tumours (Mellouki et al 2018). The most common types of malignant tumours of the small intestine are adenocarcinomas (40%), followed by neuroendocrine tumours (25%), lymphomas, and sarcomas (Zhao et al 2017). The small intestine SCA is extremely rare.…”

Section: Literature Review and Discussionmentioning

confidence: 99%

A case report and literature review of a rare primary multiple small intestinal sarcomatoid carcinoma with co-driver gene mutations

Liu,

Li,

Xie

et al. 2024

Preprint

View full text Add to dashboard Cite

Background Sarcomatoid carcinoma (SCA) is a relatively rare malignant tumor, and primary SCA occurring in the small intestine is even rarer, characterized by the co-existence of malignant epithelial cells and sarcomatoid differentiation (spindle/giant cell) components. Compared with other malignant tumors in the small intestine, it has greater invasiveness and earlier metastasis. Case presention We provide a complete case report on the clinical, imaging, genetic characterization, and treatment process of primary multiple small intestinal SCA. The patient underwent surgery, XELOX chemotherapy, and exploratory application of a multi-target tyrosine kinase inhibitor—anlotinib, however the condition progressed rapidly and he died within 3 months. This is the second report of systematic gene sequencing in the small intestine SCA, and co-mutations in key driving genes of KRAS, TP53, and PTPRT have been identified, with PTPRT being the first reported mutation in SCA. Conclusion Small intestine SCA has highly invasiveness and poor prognosis, while according to our statistical data primary multifocal small intestine SCA may have an even poor prognosis. This case was treated exploratorily with a multi-target tyrosine kinase inhibitor, anlotinib, but did not effectively control tumor growth and disease progression. This case provides reference guidance for the treatment of rare diseases such as sarcomatoid carcinoma in the future.

show abstract

Section: Literature Review and Discussionmentioning

confidence: 99%